DiscoverDiabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Claim Ownership

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Author: Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Subscribed: 15Played: 384
Share

Description

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at HCPLive.com/Clinical/Endocrinology.

Please direct podcast-related inquiries to [email protected].



Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.
223 Episodes
Reverse
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!Late-breaking data from the American Heart Association (AHA) Scientific Sessions 2026 are reopening debate on blood pressure targets in diabetes, the cardiovascular profile of dual incretin-glucagon agonists, and oral therapy for obstructive sleep apnea (OSA).On a recent episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA and their implications for cardiometabolic care.OPTIMAL-DIABETES randomized nearly 9500 adults aged 50 years and older with type 2 diabetes, elevated blood pressure, and high cardiovascular risk in Brazil to a systolic target below 120 mm Hg or below 140 mm Hg. Over roughly four years, intensive treatment lowered the relative risk of major cardiovascular events by 10%, a difference falling short of statistical significance. Achieved systolic pressures averaged about 122 mm Hg vs 135 mm Hg.The neutral result contrasts with BPROAD, a Chinese trial in which stroke reduction drove benefit from a target of <120 mm Hg. A target of <130/80 mm Hg likely remains reasonable for most patients, with lower goals individualized against dizziness, falls, electrolyte disturbances, and frailty.Survodutide, an investigational glucagon and glucagon-like peptide-1 (GLP-1) receptor dual agonist, met noninferiority for 5-point major adverse cardiovascular events in SYNCHRONIZE-CVOT. Among 5530 adults with a BMI of ≥27 kg/m² and cardiovascular disease or multiple risk factors, the primary endpoint occurred in 3.7% vs 4.1% with placebo (hazard ratio, 0.89). The CI crossed 1, and a median follow-up near 22 months limited any test of superiority.Adverse events affected 93% of participants receiving 3.6 mg or 6 mg doses vs 85.6% with placebo. Gastrointestinal events leading to discontinuation separated the groups sharply, at 19.3% and 20.8% vs 1.9%, raising questions about titration.In ATTAIN-OSA, once-daily oral orforglipron (Foundayo) reduced the apnea-hypopnea index at 52 weeks by 17.8 vs 4.5 events per hour without positive airway pressure (PAP) and by 17.3 vs 5.3 events per hour with PAP. Tirzepatide (Zepbound) already holds an OSA indication, but an oral option could reach patients averse to injections. Whether benefit extends beyond weight loss, and whether a small-molecule GLP-1 receptor agonist matches peptide cardiovascular outcomes, remains unresolved.Collectively, the trials point toward individualized blood pressure goals in diabetes and a rising evidentiary bar for incretin-based therapies, where cardiovascular benefit, tolerability, and active-comparator data will increasingly shape agent selection.Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.
In this episode of Diabetes Dialogue, co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, round up several recent developments across insulin pumps and continuous glucose monitoring. They discuss a new regulatory decision expanding wearable options for automated insulin delivery, including what it could mean for patient choice, site management, and day-to-day use. The hosts then turn to upcoming insurance coverage changes affecting glucose sensors and how practices are preparing patients ahead of the new year. They close with a look at early-stage work on the next generation of implantable sensors. Throughout, Isaacs and Bellini highlight how device design and payer decisions together shape which technologies actually reach patients.Watch the full episode on HCPLive
Triple agonism is reshaping expectations for weight loss in type 2 diabetes, a population historically less responsive to incretin-based therapy. New head-to-head phase 3 data show retatrutide more than doubled the weight reduction achieved with the highest approved dose of semaglutide (Ozempic).On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed topline results from the TRANSCEND-T2D-2 trial. Retatrutide is an investigational once-weekly agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.The open-label trial randomized 1298 adults with type 2 diabetes to retatrutide 9 mg, retatrutide 12 mg, or semaglutide 2 mg. From a mean baseline A1C of 8.3%, both retatrutide doses lowered A1C by 2.2 percentage points at 80 weeks vs 1.8 points with semaglutide. From a mean baseline weight of 102.4 kg, weight fell 19.5% with retatrutide 9 mg and 20.9% with 12 mg vs 9.4% with semaglutide.With both agents producing substantial glycemic reductions, individual weight goals may increasingly guide agent selection. Patients needing A1C lowering without large weight loss, such as frail older adults at risk for falls and fractures, may be better suited to semaglutide.Gastrointestinal events were common across all arms, with more diarrhea on retatrutide, slightly more constipation on semaglutide, and comparable rates of nausea. Discontinuation due to adverse events, however, reached 4.8% with retatrutide 9 mg and 7.9% with 12 mg vs 2.7% with semaglutide. Slower titration in practice, and use of the 9 mg dose, may help preserve tolerability without sacrificing much efficacy.Cardiovascular outcomes remain the largest open question. Semaglutide and tirzepatide (Mounjaro) both carry cardiovascular indications, while the cardiovascular effects of adding glucagon receptor agonism to GIP and GLP-1 activity are unknown. For patients with type 2 diabetes and established cardiovascular disease, agents with proven outcome benefit remain the preferred choice.Retatrutide is not FDA-approved, and compounded products of uncertain composition should be avoided. Full TRANSCEND-T2D-2 results are expected at a future medical meeting, and a placebo-controlled trial in roughly 320 adults inadequately managed with basal insulin should report in 2027.Collectively, the findings position retatrutide as a potential option for patients with type 2 diabetes who need substantial weight reduction. Tolerability at higher doses and forthcoming cardiovascular data will likely determine its place alongside established incretin therapies.Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.
Continuous glucose monitoring (CGM) is standard of care in insulin-treated diabetes, but evidence for its use in type 2 diabetes managed without insulin has lagged. New randomized data from the CONNECT trial suggest real-time CGM may substantially improve glycemic control in this much larger population.On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, FNP-BC, spoke with Tom W. Martens, MD, of the International Diabetes Center, about CONNECT, recently published in the New England Journal of Medicine.The trial enrolled 283 adults with type 2 diabetes who were not using insulin or CGM and had hemoglobin A1C levels of 7.5% or higher, across 22 primary care sites. Participants on stable non-insulin therapy were randomized 1:1 to real-time CGM with the Dexcom G7 or to routine fingerstick blood glucose monitoring (BGM) for 6.5 months. Both arms had the same number of brief, mostly virtual visits.Mean A1C in the CGM group fell from 8.8% to 7.2%, a reduction of 1.6 percentage points. The BGM group improved from 8.7% to 8.0%, for a between-group difference of 0.9 percentage points. This gap is larger than those seen in earlier randomized CGM trials in insulin-treated type 2 diabetes, including MOBILE and DIAMOND.Randomization was stratified by glucagon-like peptide-1 (GLP-1) receptor agonist use, reported by about 40% of participants at baseline. Among incretin users, A1C fell 1.4 percentage points with CGM vs 0.5 with BGM, the same 0.9-point difference. The benefit also held across other regimens, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, used by about 30% of participants, and sulfonylureas.More non-insulin therapies were added in the CGM arm. This may reflect access to continuous glucose data in place of infrequent A1C checks, which tend to reinforce clinical inertia. Much of the improvement appeared to come from lifestyle change, as participants could see postprandial excursions and link food choices to their glucose response.The current American Diabetes Association (ADA) Standards of Care give CGM a grade C recommendation in non-insulin-treated type 2 diabetes. That grade reflects limited trial evidence, not proven lack of benefit. CONNECT may supply the randomized evidence needed for a grade A rating in the 2027 Standards, and payer coverage would likely follow over time.A six-month extension, in which the BGM group switches to CGM, is still under way. Taken together, the findings suggest CGM adds to the effect of GLP-1 receptor agonists and other non-insulin therapies in primary care.Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Martens reports disclosures with Dexcom, Abbott Diabetes, Sanofi, MannKind, Zealand Pharma A/S, Lilly, and others.
On this episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, talk with Brynn Marks, MD, MSHPEd, of Breakthrough T1D about where automated insulin delivery is headed. They discuss how next-generation systems might be evaluated and what the shift could mean for people with diabetes and the clinicians who support them.Full episode: https://www.hcplive.com/view/diabetes-dialogue-a-consensus-definition-for-fully-closed-loop-systems 
loading
Comments